BioWorld - Sunday, March 8, 2026

Genitourinary/sexual function
Genitourinary/sexual function RSS Feed RSS

Renalys’ ¥6B series A to fund phase III IgAN trial in Japan

July 23, 2024
By Tamra Sami
Renalys Pharma Inc. completed a ¥6 billion (US$38.199 million) series A round that will enable it to complete a phase III trial for sparsentan for immunoglobulin A nephropathy (IgAN) in Japan. Tokyo-based Renalys in-licensed rights to sparsentan in January 2024 from Travere Therapeutics Inc. to develop the compound in Japan and 13 Asian countries to treat IgAN, a rare kidney disease.
Read More
Kidney disease illustration

Vivoryon eyes phase III after kidney win with varoglutamstat

July 18, 2024
By Randy Osborne
About four months after varoglutamstat failed in Alzheimer’s disease, Vivoryon Therapeutics NV disclosed data from the Viviad phase IIb study with the same compound in kidney disease that provided cause for hope – and Anne Doering, chief financial officer, said the new data “reinforce our strategic shift.”
Read More

Renalys’ ¥6B series A to fund phase III IgAN trial in Japan

July 17, 2024
By Tamra Sami
Renalys Pharma Inc. completed a ¥6 billion (US$38.199 million) series A round that will enable it to complete a phase III trial for sparsentan for immunoglobulin A nephropathy (IgAN) in Japan. Tokyo-based Renalys in-licensed rights to sparsentan in January 2024 from Travere Therapeutics Inc. to develop the compound in Japan and 13 Asian countries to treat IgAN, a rare kidney disease.
Read More
Biomarkers

ALG3 behind pathogenesis of preeclampsia, study unveils

July 10, 2024
Researchers have hypothesized that asparagine-linked glycosylation protein 3 homolog (ALG3) may be involved in the pathogenesis of preeclampsia by impacting the function of trophoblasts. Preeclampsia is still the leading cause of maternal and perinatal mortality and morbidity, but the mechanism behind it is still not clear.
Read More